However, the efficacy and clinical research of bee venom have not ceased. In the 1990s, breakthroughs were made in the pharmaceutical and clinical use of bee

venom around the world. Melittin, which accounts for 60% of bee venom, has become a hot topic in bee venom research in recent years due to its excellent hemolytic

properties. In 2002, a new anti-cancer drug mainly composed of melittin, developed by Australian scientists, has entered clinical trials. Studies have shown that bee venom contains certain enzymes and peptide substances, which have a certain anesthetic effect on organisms. The venom enzyme in snake venom has always been regarded as having good hemolytic properties, and the hemolytic property of melittin is even better - its molecule is small and easier to penetrate. Moreover, because it is an insect toxin, it is very safe.

Based on the exploration of the ancient bee needle therapy, our hospital developed an internationally leading electronic automatic bee venom collector in 1979.

It was granted a national invention patent in 1988 and won the National Invention Award in 1996. This technology can collect high-purity bee venom without harming bees, further promoting the application of bee venom. In 1996, China's first provincial bee therapy hospital and

research institute were established, and in 2001, a new bee therapy major was set up.

Shenfeng Technology